Cancer research
Trials across solid tumours, blood cancers, immunotherapy and supportive care.
4,238 indexed studies · 1,758 currently recruiting
Top conditions in this hub
Recent studies
- RecruitingPHASE1, PHASE2
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
This study is testing a new medicine called S241656 for people with certain advanced cancers, including lung, bowel, and pancreatic cancers. It aims to find a safe and effective dose, either alone or with other treatments, for cancers with specific genetic changes.
United States · Denmark · Hong Kong - RecruitingNA
Exercise to Improve Outcomes in Pancreatic Cancer
This study looks at a special exercise program for people having surgery for pancreatic cancer. It aims to see if exercising before, during, and after surgery helps with recovery and makes it easier to start other treatments. It's the first step to see if this program can work.
United Kingdom - RecruitingPHASE3
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
This study is looking for better ways to treat advanced kidney cancer that has come back after earlier treatment. Researchers want to see if a new combination of medicines, belzutifan and zanzalintinib, works better than a standard medicine, cabozantinib, at shrinking the cancer.
United States · Argentina · Australia - RecruitingPHASE3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
This study is testing a new drug, rilvegostomig, against a standard treatment, pembrolizumab, for advanced lung cancer. It's for people whose cancer has spread and has high levels of a specific marker called PD-L1. The aim is to see which treatment works better and is safer.
United States · Argentina · Australia - RecruitingPHASE3
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
This study is for people with advanced bowel cancer that has spread and has a specific gene change called KRAS p.G12C. It compares a new combination of treatments to standard treatment to see if it can better stop the cancer from growing.
United States · Argentina · Australia - RecruitingPHASE3
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
This study compares a new treatment, TAR-210, with standard chemotherapy for high-risk bladder cancer that hasn't spread to the muscle. It aims to see which treatment best prevents the cancer from returning or getting worse.
United States · Argentina · Belgium - RecruitingPHASE3
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
This study looks at new drug combinations for advanced breast cancer. It compares saruparib and camizestrant with common existing treatments to see which works best for people with specific genetic changes (BRCA1, BRCA2, or PALB2m) in their cancer.
United States · Argentina · Australia - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
United States · Argentina · Australia - RecruitingPHASE3
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new drug, Telisotuzumab Vedotin, against a standard treatment, Docetaxel, for advanced non-small cell lung cancer. It aims to see if the new drug works better and is safe for adults who have already had treatment.
United States · Argentina · Australia - Recruiting
To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.
This study looks at how well a special scan, called PET-CT, works on removed cancer tissue. It compares these scans with lab results and patient health over time to see if this technology can improve cancer care and treatment decisions.
Belgium · Germany · Netherlands - Ongoing, recruitingTherapeutic exploratory (Phase II)
KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
This study is testing different new drug combinations with pembrolizumab and chemotherapy for people with advanced non-small cell lung cancer who haven't had treatment yet. It's looking at how well the new combinations shrink tumors and if they have side effects.
Italy · Hungary · Poland - Ongoing, recruitingTherapeutic exploratory (Phase II)
A MULTICOHORT, OPEN LABEL, PHASE 2 STUDY OF BOTENSILIMAB (AGEN1181) FOR TREATMENT OF ADVANCED MELANOMA REFRACTORY TO PRIOR CHECKPOINT INHIBITOR THERAPY
This study is testing new medicines, botensilimab and balstilimab, for adults with advanced melanoma. These are cancers that have not responded to previous treatments. We want to see if the new medicines can shrink the cancer.
Belgium · Germany · Italy - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
First-in-Human, Open-label, Dose-Escalation Trial with Expansion Cohorts to Evaluate the Safety of GEN1053 as Monotherapy and in Combination With an Immunomodulator in Subjects with Malignant Solid Tumors
This study is testing a new medicine called HexaBody-CD27 for people with solid tumours that have spread. It's looking at how safe the medicine is, how much to give, and if it can help shrink tumours. It's an early-stage study to understand this new treatment better.
Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
This study looks at a new drug, pembrolizumab (Keytruda), combined with another medicine, enzalutamide. It's for men with advanced prostate cancer that has spread and isn't responding to hormone treatment. We want to see if this combination helps men live longer and slows down the cancer's growth.
Austria · Italy · Netherlands - Ongoing, recruitingTherapeutic use (Phase IV)
The Intertransverse Process Block - Single or Multiple Injection? A randomised, procedure related, blinded crossover trial in healthy volunteers
This study is looking at a pain-relief method called an 'Intertransverse Process Block' in healthy men. Researchers are comparing one injection to multiple injections to see which works better for numbing areas of the chest. It's about finding the best way to help with pain, especially after breast cancer surgery.
Denmark - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC)
This study is testing a new medicine, cemiplimab (also known as Libtayo), for a type of skin cancer called cutaneous squamous cell carcinoma. Doctors want to see if giving this medicine before surgery can completely clear the cancer cells at the original site.
Germany - Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients with Selected Advanced Solid Tumors
This study is testing a new medicine, ADCT-901, for people with advanced cancers that have spread. It's the first time this medicine is being given to humans, to see how safe it is, what side effects it has, and if it helps shrink tumours.
Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Intratumoral Injection of LTX-315 in Combination with Pembrolizumab in Patients with Percutaneously Accessible Lesions with Advanced Melanoma Refractory to PD-1/PD-L1 Inhibitor Therapy
This study looks at a new treatment for advanced melanoma that has not responded to previous immunotherapy. It combines an injected drug (LTX-315) with an existing cancer drug (Pembrolizumab) to see if it can shrink tumours and extend life. Researchers will closely monitor participants' health.
France · Norway · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Various Combinations of BGB-A425 and LBL-007 with Tislelizumab in Patients with Advanced Solid Tumors
This study looks at new drug combinations (BGB-A425, LBL-007, and Tislelizumab) for advanced head and neck, kidney, and lung cancers. It aims to find safe doses and see if they shrink tumours. It's an early-stage study.
France · Spain · Poland - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase I/II study to evaluate the feasibility, safety and preliminary efficacy of point-of-care manufactured anti-CD19 CAR T in subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
This study is looking at a new treatment called BCN-CP01 for people with certain types of blood cancer (relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma) that have come back or not responded to previous treatments. It aims to see if the treatment is safe and if it helps patients get better.
Spain · Belgium · Netherlands - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Phase 1b study investigating the association of NP137 with mFOLFIRINOX in locally advanced pancreatic ductal adenocarcinoma LAP NET 1
This study is looking at a new treatment called NP137 when given alongside a common chemotherapy for pancreatic cancer. It's for adults with a type of pancreatic cancer that hasn't spread far but can't be removed by surgery. The aim is to see if these treatments work well together.
France - Ongoing, recruitingTherapeutic exploratory (Phase II)
Ezurpimtrostat autophagy inhibitor in association with Atezolizumab-Bevacizumab in first line treatment of unresectable hepatocellular carcinoma, a phase 2b randomized trial. ABE-LIVER
This study is testing a new drug, Ezurpimtrostat, alongside standard treatments (Atezolizumab and Bevacizumab) for advanced liver cancer that can't be removed by surgery. It aims to see how well this new combination stops the cancer from growing.
France - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1 Study of the SHP2 Inhibitor BBP-398 (formerly known as IACS-15509) in combination with the KRAS-G12C Inhibitor Sotorasib in Patients with Advanced Solid Tumors and a KRAS-G12C Mutation
This study is testing a new combination of two medicines for people with advanced cancers that have a specific genetic change (called KRAS-G12C). One medicine is new (BBP-398), and it's being given with an existing one (sotorasib) to see if they work better together.
Netherlands · Spain · France - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Phase 1 study of NG-641 plus nivolumab (or standard of care PD-1) in metastatic or advanced epithelial tumours (NEBULA)
This study is looking into a new treatment called NG-641, used with an existing cancer medicine (nivolumab or similar), for people with advanced or spreading cancer. It's a very early-stage trial, focusing on safety and how the new treatment works in the body.
Belgium · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase 2, Open-Label Study in Subjects with Previously Untreated MET Amplified Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
This study is testing a new medicine, Telisotuzumab Vedotin, for people with a specific type of lung cancer that hasn't been treated before. Researchers want to see how well it shrinks tumours and helps patients feel better. It's an important step in finding new treatments.
Romania · Germany · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
This study looks at a new drug, DKN-01, combined with standard treatments for advanced bowel cancer. It compares this new combination to the standard treatments alone, to see if it helps people live longer without their cancer growing.
Germany - RecruitingNA
IMPLEMENT - Model Project for Quality-assured Exercise Therapy for Cancer Patients
This project aims to make sure cancer patients in Germany can easily access high-quality exercise programmes. It will find out what helps and what makes it difficult for people to join these programmes, and then create better ways for everyone to get involved.
Germany - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Study of BMS-986408 Alone and in Combination with Nivolumab or with Nivolumab and Ipilimumab in Participants with Advanced Solid Tumors
This study is testing a new drug, BMS-986408, alone and with existing cancer drugs, nivolumab and ipilimumab, for advanced solid tumours. It aims to see how safe the new drug is and what side effects it might cause, as well as how well it works.
France · Spain - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A 3-Part Phase 1 Study to Investigate the Absolute Oral Bioavailability and Absorption, Metabolism, and Excretion of 14C-Unesbulin in Patients With Advanced Solid Tumor
This early-stage study is testing a new medicine called Unesbulin, marked with a special tracer, in people with advanced solid tumours. Researchers want to understand how the body takes in, uses, and gets rid of this medicine when taken by mouth.
Hungary - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients with Advanced Gastrointestinal Stromal Tumors (GIST)
This study is testing a new medicine, THE-630, for people with a type of cancer called GIST. It's looking at how safe the medicine is, how it moves through the body, and if it helps shrink tumours. It's in early stages, checking different doses.
Spain · France - RecruitingNA
Lymph Node Mapping Via Flourescent Dye in Colon Cancer
This study looks at how cancerous colon cells spread to nearby lymph nodes. We use a special dye and camera during surgery to see if these nodes are always found in the usual places, or sometimes outside, which could help guide treatment.
Germany - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Open-Label Multicenter Trial to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects with BRAF-V600 Mutant Solid Tumors.
This study is testing a new medicine, CFT1946, for people with certain types of cancer that have a specific BRAF gene change. It checks if the medicine is safe, how well it's tolerated, and if it can shrink tumors or stop them growing, both alone and with other treatments.
France · Spain · Italy - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
Phase 1b study to evaluate MK 0482 for Relapsed/Refractory AML/CMML
This early-stage study is looking at a new medicine called MK 0482 for adults with certain types of blood cancer (AML or CMML) that have come back after treatment or haven't responded well. It aims to see if the medicine is safe and how it works.
Spain - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1 Study of BMS-986360/CC-90001 Alone and in Combination with Chemotherapy or Nivolumab in Advanced Solid Tumors
This study is testing a new medicine, BMS-986360/CC-90001, for people with advanced solid cancers. It will see how safe the medicine is when given alone or with other cancer treatments like chemotherapy or nivolumab. It's an early-stage study, meaning it's the first time it will be widely used in people.
Italy · Spain · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL).
This study is testing a new cell therapy called ALLO-501A, along with another drug called ALLO-647, for adults with a type of blood cancer called Large B-Cell Lymphoma, where previous treatments haven't worked. It aims to see how safe and effective these new treatments are.
Italy · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti-PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma
This study is testing a new medicine, ALE.C04, alone and with an existing drug, Pembrolizumab, for head and neck cancer that has come back or spread. It will check if the new medicine is safe and if it can help shrink the cancer.
Italy · Spain · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
"DEMETER": Milademetan and fulvestrant in GATA3-mutant, ER-positive, HER2-negative advanced or metastatic breast cancer patients: a multicenter phase II trial
This study is testing a new drug, milademetan, alongside an existing treatment, fulvestrant, for a specific type of advanced breast cancer. Researchers want to see if this combination helps shrink tumours or stop their growth in patients with certain genetic markers.
France - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Phase 1 study of NG-350A plus pembrolizumab in metastatic or advanced epithelial tumours (FORTIFY)
This study, called FORTIFY, is testing a new treatment called NG-350A along with an existing cancer drug, pembrolizumab. It's for adults with advanced or spreading cancers that start in the lining of organs, like skin or glands. This is an early-stage study to see if the treatment is safe.
Belgium · Spain - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Z0011001-A PHASE 1/2, OPEN-LABEL, MULTI-CENTER STUDY OF ZN-c3 ADMINISTERED IN COMBINATION WITH ENCORAFENIB AND CETUXIMAB IN ADULTS WITH METASTATIC COLORECTAL CANCER
This study is testing a new combination of medicines for people with bowel cancer that has spread. We want to see if a new drug called Azenosertib, given with two existing drugs (Encafenib and Cetuximab), is safe and helps shrink the cancer. This is an early-stage study.
Poland · Spain · Germany - Ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1, Open-label, Multicenter Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MK-4464 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced/Metastatic Solid Tumors
This early-stage study is testing a new medicine, MK-4464, alone and with another drug (pembrolizumab). It's for adults with advanced cancers to see if it's safe, how it moves through the body, and what effects it has. This is one of the first times it's being used in people.
Netherlands